Publication: Weekly continuous infusion of 5-fluorouracil with oral leucovorin in metastatic breast cancer patients with primary resistance to doxorubicin
Authors
Nieto, Yago ; Martín, Miguel ; Alonso-Romero, José Luis ; Casado, Antonio ; Ayala, Francisco ; López-Martín, José Antonio ; Rodríguez-Lescure, Alvaro ; Díaz-Rubio, Eduardo
item.page.secondaryauthor
item.page.director
Publisher
Springer
publication.page.editor
publication.page.department
DOI
https://doi.org/10.1023/a:1006062018355
item.page.type
info:eu-repo/semantics/article
Description
© 1998 kluwer Academic Publisher. This document is the Published version of a Published Work that appeared in final form in Breast Cancer Research and Treatment. To access the final edited and published work see https://doi.org/10.1023/a:1006062018355
Abstract
Doxorubicin-resistant metastatic breast cancer (MBC) is a very poor prognosis scenario, where only taxanes have shown activity, often at the expense of severe toxicity that compromises palliation. This study was undertaken to test the antitumor activity and tolerability of infusional 5-fluorouracil (5-FU) modulated with low-dose oral leucovorin (LV), in heavily pretreated patients with stringent criteria of primary resistance to doxorubicin, visceral involvement, and suboptimal performance status. Twenty-six patients with measurable MBC and primary resistance to anthracyclines received a weekly outpatient 48-hour infusion of high-dose 5-FU with low dose oral leucovorin. All patients were assessable for response and toxicity. Eight partial responses were seen (30% response rate) in soft tissue and visceral sites, with a median response duration of eight months (5 + to 12). 98% of the cycles were minimally toxic or non-toxic. Toxicities included mucositis, diarrhea, and plantar-palmar-syndrome. Our results suggest that this schedule of LV-modulated infusional 5-FU can produce a substantial number of long-lasting responses and meaningful palliation to this very poor prognosis population.
publication.page.subject
Citation
Breast Cancer Research and Treatment 50: 67–174, (1998)
item.page.embargo
Collections
Ir a Estadísticas
Sin licencia Creative Commons.